Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 11/20 | 0.59 |
| ▸ | KCNMA1 | Q12791 | 9/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275016 | 0.89 | PDE9A (0.69) | PDE9AKCNMA1 | |
| SCHEMBL24276371 | 0.86 | PDE9A (0.61) | PDE9AKCNMA1 | |
| SCHEMBL24063457 | 0.86 | PDE9A (0.61) | PDE9AKCNMA1 | |
| SCHEMBL24276300 | 0.86 | PDE9A (0.64) | PDE9AKCNMA1 | |
| SCHEMBL24063519 | 0.86 | PDE9A (0.64) | PDE9AKCNMA1 | |
| SCHEMBL22275267 | 0.85 | PDE9A (0.62) | PDE9AKCNMA1 | |
| SCHEMBL24063456 | 0.85 | PDE9A (0.62) | PDE9AKCNMA1 | |
| SCHEMBL24063523 | 0.85 | PDE9A (0.70) | PDE9AKCNMA1 | |
| SCHEMBL24276306 | 0.85 | PDE9A (0.70) | PDE9AKCNMA1 | |
| SCHEMBL22275170 | 0.85 | PDE9A (0.70) | PDE9AKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE9A, PDE12, PDE5A | PDE9A 1/4885KCNMA1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.